Annual International Primary CNS Lymphoma Collaborative Group Meeting

描述（由申请人提供）：原发性中枢神经系统淋巴瘤（PCNSL）是局限于神经系统的非霍奇金淋巴瘤（NHL）的淋巴结变异。PCNSL的诊断和治疗方法与应用于其他形式的NHL或其他脑癌的方法不同。国际原发性中枢神经系统淋巴瘤协作组（IPCG）由来自多个国家和学科的专家组成，致力于PCNSL的研究。IPCG在美国血液学会会议上举行年度科学会议，讨论与PCNSL相关的各种研究主题。每年由一个执行委员会选出一名所讨论专题的国际专家主持科学会议。这些会议促成了多个合作项目，这些项目对该领域产生了影响，并已发表在同行评审文献中。IPCG年会是一个重要的论坛，为这种独特的脑癌形式提供新的想法和方法。 公共卫生相关性：国际原发性中枢神经系统淋巴瘤（PCNSL）协作组（IPCG）每年举行一次年度科学会议，以审查研究进展，并对PCNSL产生新的想法，PCNSL是一种脑内非霍奇金淋巴瘤。年度会议在刺激参与治疗这种类型的淋巴瘤的许多不同专家之间的国际合作方面非常成功。这些合作导致了临床试验和新的工具来研究这组患者的结果。

DESCRIPTION (provided by applicant): Primary central nervous system lymphoma (PCNSL) is an extranodal variant of non- Hodgkin lymphoma (NHL) that is confined to the nervous system. The diagnostic and therapeutic approaches to PCNSL are different from those that are applied to other forms of NHL or to other brain cancers. The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) consists of specialists from multiple countries and disciplines dedicated to the study of PCNSL. The IPCG holds an annual scientific conference at the American Society of Hematology meeting in which various research topics related to PCNSL are discussed. An international expert on the topic under discussion is selected each year by an executive committee to chair the scientific conference. These meetings have led to multiple collaborative projects that have impacted the field and that have been published in the peer-reviewed literature. The annual IPCG meeting is a critical forum for generating new ideas and approaches to this unique form of brain cancer. PUBLIC HEALTH RELEVANCE: The International Primary Central Nervous System Lymphoma (PCNSL) Collaborative Group (IPCG) holds an annual scientific conference each year to review research progress and to generate new ideas on PCNSL, a type of non-Hodgkin lymphoma in the brain. The annual conference has been very successful in stimulating international collaboration among the many different specialists involved in the treatment of this type of lymphoma. These collaborations have led to clinical trials and new tools to study outcomes in this group of patients.